Results 221 to 228 of about 330,013 (228)

VAD‐based regimens as primary treatment for multiple myeloma

American journal of hematology/oncology, 1990
R. Alexanian, B. Barlogie, S. Tucker
semanticscholar   +1 more source

Proposed policy for vad removal

The Annals of Thoracic Surgery, 2002
Kenneth M. Prager, Mehmet C. Oz
openaire   +3 more sources

Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial

, 2008
J. Harousseau, C. Mathiot, M. Attal, G. Marit, D. Caillot, Cyrille Hullin, T. Facon, I. Webb, H. Avet-Loiseau, P. Moreau   +9 more
semanticscholar   +1 more source

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

, 2008
P. Sonneveld, B. Holt, I. Schmidt-Wolf, U. Bertsch, L. E. Jarari, H. Salwender, S. Zweegman, E. Vellenga, J. Schubert, I. Blau, G. Jie, B. Beverloo, A. Jauch, D. Hose, R. Schaafsma, M. Kersten, M. Delforge, O. Weerdt, R. Griend, P. Wijermans, H. Martin, H. Velde, H. Lokhorst, H. Goldschmidt   +23 more
semanticscholar   +1 more source

Understanding patients with VADs

Critical Care Nurse, 2010
openaire   +2 more sources

Editorial Comments on “VAD or Transplant”

Cardiology Clinics, 2011
openaire   +3 more sources

The VAD Journal

openaire   +1 more source

Poul Vads anatomi

1998
openaire   +1 more source